This episode was hosted by Anne Donohoe and Nick Opich of KCSA Strategic Communications. Links to the guest’s company and social media accounts Previously, he served in senior investment banking roles at Desjardins Securities and Sandfire Securities, and in CEO, CFO and corporate director roles for private and public companies. He’s an entrepreneur and the principal of Emmcap Corp., an investor in venture-stage companies. Yaron Conforti is the Chief Executive Officer and Director of Novamind. Yaron Conforti, Chief Executive Officer of Novamind So don’t sit back, lean forward and enjoy! As psychedelic investors look for opportunities, they won’t want to miss this interview with Yaron as he delves into how his company is focused on execution and bringing these next-generation treatments to the masses. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine.Īs the psychedelic renaissance continues to take shape, our hosts Anne and Nick sat down with Yaron to chat with him about the more than 4,000 ketamine-assisted psychotherapy treatments Novamind has administered, the Company’s expansion plans beyond its home base of Utah and Novamind’s RTO onto the CSE. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Yaron Conforti, CEO and Director of Novamind Ventures (CSE: NM), which delivers psychedelic therapies to patients suffering from treatment resistant psychological conditions at its Cedar Psychiatry clinics in Utah, is this week’s special guest on The Green Rush.
0 kommentar(er)
